Cargando…

Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance

This cohort study examines whether hydroxyurea use changes in young adults with sickle cell disease who are transitioning from pediatric to adult health care.

Detalles Bibliográficos
Autores principales:	Mathias, Joacy G., Nolan, Vikki G., Klesges, Lisa M., Badawy, Sherif M., Cooper, William O., Hankins, Jane S., Smeltzer, Matthew P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515209/ https://www.ncbi.nlm.nih.gov/pubmed/34643722 http://dx.doi.org/10.1001/jamanetworkopen.2021.28971

Ejemplares similares

Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach
por: Alberts, Nicole M, et al.
Publicado: (2020)

Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell Program
por: Nottage, Kerri A., et al.
Publicado: (2013)

Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study
por: Badawy, Sherif M, et al.
Publicado: (2022)

From Infancy to Adolescence: Fifteen Years of Continuous Treatment With Hydroxyurea in Sickle Cell Anemia
por: Hankins, Jane S., et al.
Publicado: (2014)

Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents
por: Reddy, Paavani S., et al.
Publicado: (2022)

A meta‐analysis of toxicities related to hydroxycarbamide dosing strategies
por: Mathias, Joacy G., et al.
Publicado: (2020)

Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA
por: Smeltzer, Matthew P, et al.
Publicado: (2021)

Intensive hydroxyurea dosing in very young children with sickle cell anemia
por: Wang, Winfred C., et al.
Publicado: (2023)

Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults
por: Badawy, Sherif M., et al.
Publicado: (2017)

Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study
por: Hankins, Jane S, et al.
Publicado: (2020)

The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease
por: Kang, Hyeun Ah, et al.
Publicado: (2020)

Prevalence of Vitamin D Deficiency in Sickle Cell Disease: A Systematic Review
por: Nolan, Vikki G., et al.
Publicado: (2015)

Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review
por: Yang, Mira, et al.
Publicado: (2022)

Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease
por: Hankins, J. S, et al.
Publicado: (2023)

A Retrospective Review to Determine If Children with Sickle Cell Disease Receive Hydroxyurea Monitoring
por: Creary, Susan E., et al.
Publicado: (2017)

A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study
por: Creary, Susan, et al.
Publicado: (2019)

Changes in Hydroxyurea Use Among Youths Enrolled in Medicaid With Sickle Cell Anemia After 2014 Revision of Clinical Guidelines
por: Reeves, Sarah L., et al.
Publicado: (2023)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Implementation and Preliminary Effectiveness of mHealth Apps for Improving Sickle Cell Disease Care during COVID-19: A Mixed-Methods Evaluation
por: Badawy, Sherif M., et al.
Publicado: (2021)

Trends in Tennessee Medicaid Acute Care: Use and Expenditures, 1974-1978
por: Cromwell, Jerry L., et al.
Publicado: (1982)

Transitional care innovation for Medicaid-insured individuals: early findings
por: Brooks Carthon, J Margo, et al.
Publicado: (2022)

Insurance Coverage Transitions After Disenrollment From Medicaid in Minnesota
por: Frenier, Chris, et al.
Publicado: (2023)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

The Impact of Medicaid Expansion on Medicaid Focused Insurers in California
por: McCue, Michael J.
Publicado: (2015)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Patient-Centered eHealth Interventions for Children, Adolescents, and Adults With Sickle Cell Disease: Systematic Review
por: Badawy, Sherif M, et al.
Publicado: (2018)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease
por: Green, Nancy S., et al.
Publicado: (2013)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
por: Wong, Trisha E., et al.
Publicado: (2021)

Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease
por: Pandey, Akancha, et al.
Publicado: (2022)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

Exposures Associated with Non-Typhoidal Salmonella Infections Caused by Newport, Javiana, and Mississippi Serotypes in Tennessee, 2013–2015: A Case-Case Analysis
por: Mukherjee, Nabanita, et al.
Publicado: (2020)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

The Tennessee Medicaid medication therapy management program: early stage contextual factors and implementation outcomes
por: Hohmeier, Kenneth C., et al.
Publicado: (2021)

Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia
por: Silva, Danilo Grunig Humberto, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4gsecc4bts3c76pjlssg61dcj0